Estriol
As of the edition of 20 October 2026, Estriol is a small molecule: marketed, first approved in 1958 (CH); acts on ESR1 and ESR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1989
- Kind
- Small molecule
- Brand name
- Ovestin
- First approved
- 17 May 1958 (CH)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- Aspen Pharma Trading Limited; 3 holders in all
- Registered trials
- 13, 1 stopped early
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Immune system; Nervous system; Cancer; Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 2 | 1 | 0 |
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 4 | 2 | 0 | 1 |
| Phase 3 | 3 | 2 | 1 | 0 |
| All trials | 13 |